Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
LGVN is expected to report earnings to fall 20.37% to -21 cents per share on May 10
Q1'24
Est.
$-0.22
Q4'24
Missed
by $0.07
Q4'23
Missed
by $0.81
Q3'23
Missed
by $0.05
Q2'23
Missed
by $0.02
The last earnings report on February 28 showed earnings per share of -27 cents, missing the estimate of -20 cents. With 69.59K shares outstanding, the current market capitalization sits at 17.71M.